Top Markets
Coin of the day
Kidswell Bio Corporation Kidswell Bio Corporation

Kidswell Bio Corporation

4584
Rang in Aktien #24939
Kidswell Bio Corporation, headquartered in Tokyo, Japan, specializes in the... Kidswell Bio Corporation, headquartered in Tokyo, Japan, specializes in the development of pharmaceutical treatments for rare and complex diseases. The company, which was founded in 2001 and operated as Gene Techno Science Co.,Ltd. until rebranding in July 2021, maintains a robust pipeline of therapeutic candidates. This includes GND-004, designed for both ophthalmic conditions and oncology, and GND-007, aimed at immunological disorders. Their portfolio also features a range of antibodies being developed for cancer therapies. Further expanding its research, the GBS series encompasses GBS-001, GBS-004, and GBS-010 for oncology; GBS-005 for immunological diseases; GBS-007 and GBS-012 for eye-related ailments; GBS-008 for infectious diseases; and GBS-011 for renal conditions. Additionally, Kidswell Bio is progressing GCT-101 for alveolar clefts, GCT-102 for congenital isolated hypoganglionosis, alongside other investigational products addressing ophthalmologic disorders, cerebral palsy, peripheral nerve palsy, fractures, and spinal cord injuries.
Aktienkurs
$1.11
Marktkapitalisierung
$55.05M
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
-36.23%
Land
JP
Handel Kidswell Bio Corporation (4584)

Kategorie

P/B-Verhältnis für Kidswell Bio Corporation (4584)
P/B-Verhältnis zum 2026 TTM: 0
Laut den neuesten Finanzberichten und dem Aktienkurs von Kidswell Bio Corporation beträgt das aktuelle Kurs-Buchwert-Verhältnis (TTM) 0. Am Ende des Jahres 2026 lag das P/B-Verhältnis bei 0.
P/B-Verlauf für Kidswell Bio Corporation von 2026 bis 2026
P/B-Verhältnis zum Jahresende
Jahr P/B-Verhältnis ändert
Nicht genügend Daten für die angegebenen Daten.
P/B-Verhältnis für ähnliche Unternehmen oder Wettbewerber
Unternehmen P/B-Verhältnis P/B-Verhältnis-Differenz Land
6.3419 -
US
6.2413 -
NL
2.5054 -
AU
- -
CH
3.7087 -
US